about
The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study.Study design and rationale for biomedical shirt-based electrocardiography monitoring in relevant clinical situations: ECG-shirt study.Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials.Adherence to systolic heart failure guidelines in ambulatory care in Poland - data from the international QUALIFY survey.Prevalence of depressive disorders in professional drivers - epidemiologic subanalysis of the RACER study.Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries).Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart Failure Long-Term Registry).Predictors of one-year outcome in patients hospitalised for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology.Resting heart rate at hospital admission and its relation to hospital outcome in patients with heart failure.Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran and rivaroxaban: results from the CRAFT study.OCULUS study: Virtual reality-based education in daily clinical practice.Heart failure patients with a previous coronary revascularization: results from the ESC-HF Registry.Appropriate and effective interventions of subcutaneous implantable cardioverter-defibrillator (S-ICD): single-academic-centre experience.The influence of the atrial fibrillation episode duration on the endothelial function in patients treated with pulmonary veins isolation.Do β-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF RegistryIn-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term RegistriesCharakterystyka kliniczna i czynniki prognostyczne w rocznej obserwacji pacjentów z niewydolnością serca i migotaniem przedsionków w porównaniu z chorymi z niewydolnością serca i rytmem zatokowymClinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF studyRandomized controlled clinical trials versus real-life atrial fibrillation patients treated with oral anticoagulants. Do we treat the same patients?Clinical characteristics and 1-year outcome of hyponatremic patients hospitalized for heart failureHeart failure in elderly patients: differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF Long-Term RegistryTreatment of heart failure in the elderly in Poland. The results of the Polish part of EURObservational Research Programme: The Heart Failure Pilot SurveyComparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trialSmoking ban in public places and myocardial infarction hospitalizations in a European country with high cardiovascular risk: insights from the Polish nationwide AMI-PL databaseTrends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term RegistryResistin is a prognostic factor for death in type 2 diabetes
P50
Q37602424-8A22F081-C6DA-43F3-BFE6-1D5BD209F98FQ37703289-747D9E5A-B2E3-4239-A588-EE64835ECF41Q38371680-3A6972A5-6808-469A-AC69-8795F9734BD7Q38552492-43E08A4D-F561-4489-9FF3-D915606423FCQ38635237-8B7E63BF-1EC3-48E4-8B24-2E92B49443F9Q39185030-87749694-BB7D-4ACA-8E2B-EDE391510683Q40231179-8003467C-E00C-486E-9AB6-966227CC2700Q40668997-52EFCC7B-4DF6-4108-B946-7E28D8D67F4CQ41649231-8C0EDD4E-DEA7-4844-9623-14F85F9C4009Q46123149-380EA98A-A47A-440F-BAA3-2850102F033BQ47551351-5BC3E3F5-81DA-437B-A0D4-2A57BCE9FBA8Q49350112-27FE4588-74BA-4D52-A4D7-B1F87AFEDBE2Q49587776-A86FF293-5AA7-4967-8CF8-0BA87810A723Q49852608-B636A32C-0A8E-4184-A280-6DF7A3BB4AF4Q50736344-57370B0F-C242-4DA4-9355-B86FA7AD0FCDQ57286226-80FF6E5D-7BF5-44C2-BC0A-0EF61D6C0003Q57628367-C636DBF2-4A62-4099-9220-9B394DEDEC12Q57628529-73D5BD4B-979B-4D47-B91B-EF229EA60EF3Q58567579-8D47CD3E-5CDA-4E65-A4FC-7D13E405F13CQ58577496-E958B134-AE0D-4F45-B4EE-3BCE054B95A1Q86643540-89B95740-85D3-4554-BB9B-B29E6EA6B1BCQ88097558-72D8BA1C-24F1-4260-BBE5-7789F6745E63Q91843583-796E184C-6CE1-443A-A2BB-7CDA42DC4A51Q92467087-8B419DF4-F035-42BF-AFD9-1748C73A622BQ92556880-0D72A0B5-7960-4346-AF25-412FC0908FAAQ92906965-560642D3-A801-48CC-84E7-21537DF422BEQ93186071-C15D303F-C80B-4083-AB74-C182663C34BF
P50
description
Polish researcher
@en
Pools onderzoeker
@nl
polski naukowiec
@pl
taighdeoir Polannach
@ga
name
Krzysztof Ozierański
@ast
Krzysztof Ozierański
@ca
Krzysztof Ozierański
@de
Krzysztof Ozierański
@en
Krzysztof Ozierański
@es
Krzysztof Ozierański
@fr
Krzysztof Ozierański
@ga
Krzysztof Ozierański
@gl
Krzysztof Ozierański
@it
Krzysztof Ozierański
@nl
type
label
Krzysztof Ozierański
@ast
Krzysztof Ozierański
@ca
Krzysztof Ozierański
@de
Krzysztof Ozierański
@en
Krzysztof Ozierański
@es
Krzysztof Ozierański
@fr
Krzysztof Ozierański
@ga
Krzysztof Ozierański
@gl
Krzysztof Ozierański
@it
Krzysztof Ozierański
@nl
prefLabel
Krzysztof Ozierański
@ast
Krzysztof Ozierański
@ca
Krzysztof Ozierański
@de
Krzysztof Ozierański
@en
Krzysztof Ozierański
@es
Krzysztof Ozierański
@fr
Krzysztof Ozierański
@ga
Krzysztof Ozierański
@gl
Krzysztof Ozierański
@it
Krzysztof Ozierański
@nl
P214
P106
P1153
55955787800
P1412
P1559
Krzysztof Ozierański
@pl
P21
P214
P27
P31
P496
0000-0002-3848-0922
P735
P7859
viaf-315211980